Retham Technologies Launches Next-Generation Cryoplatelets to Improve Platelet Research and Laboratory Testing
Retham Technologies, Inc. has announced the commercial launch of Retham Cryoplatelets™, a next-generation functional platelet product developed to address one of the most persistent challenges in biomedical research—the limited availability and variability of fresh human platelets used in laboratory testing.
Alongside the product launch, the company also revealed a strategic distribution partnership with Prolytix, a recognized provider of coagulation and hematology services, products, and laboratory solutions. Under the agreement, Prolytix will distribute Retham Cryoplatelets to research organizations, academic institutions, pharmaceutical companies, biotechnology firms, and contract research organizations (CROs), helping expand access to this innovative research tool.
The introduction of Retham Cryoplatelets represents an important advancement for platelet-based research by providing investigators with a reliable, standardized, and readily available source of functional human platelets that can be stored and used on demand. By eliminating many of the logistical and scientific limitations associated with freshly collected donor platelets, the new technology aims to improve reproducibility, operational efficiency, and scalability across a wide range of laboratory applications.
Addressing a Longstanding Challenge in Platelet Research
Human platelets play a central role in blood clotting, wound healing, inflammation, immune responses, and numerous cardiovascular processes. Because of these diverse biological functions, they are essential tools in both basic scientific research and pharmaceutical development.
Researchers routinely use platelets to investigate blood coagulation disorders, evaluate the effectiveness of anti-clotting medications, study platelet activation pathways, develop new therapeutics, and assess the safety of biological drugs.
However, obtaining functional human platelets has historically presented significant challenges.
Traditional laboratory research depends heavily on freshly drawn donor platelets, which have an extremely limited shelf life. Fresh platelets must be collected, processed, transported, and used within a relatively short period before their biological activity declines.
This requirement creates numerous logistical obstacles for laboratories, particularly those conducting large research programs or operating in locations without immediate access to blood donation facilities.
In addition to supply limitations, platelet function can vary considerably from one donor to another. These natural biological differences introduce experimental variability that can complicate data interpretation, reduce reproducibility, and increase the number of experiments required to generate reliable results.
A Stable, Functional Alternative
Retham Technologies developed Cryoplatelets specifically to overcome these longstanding limitations.
Unlike conventional fresh donor platelets, Retham Cryoplatelets are cryopreserved while maintaining important functional characteristics needed for laboratory testing.
Because they can be stored for extended periods and thawed when needed, researchers no longer have to coordinate experiments around donor availability or fresh blood collections.
Instead, laboratories gain immediate access to standardized platelet preparations that can be incorporated into research workflows whenever required.
The company states that the product has been engineered to retain responsiveness across multiple assay platforms, allowing investigators to conduct platelet function testing using a dependable and consistent biological reagent.
This approach provides operational flexibility while reducing many of the scheduling constraints associated with fresh platelet procurement.
Improving Reproducibility in Scientific Research
One of the most important advantages of Retham Cryoplatelets is their potential to improve reproducibility across scientific studies.
Reproducibility has become a major focus throughout biomedical research, with investigators increasingly seeking standardized materials capable of reducing experimental variation.
Donor-to-donor variability remains one of the largest uncontrolled variables in platelet-based assays.
Even healthy donors may exhibit differences in platelet activation, receptor expression, responsiveness to agonists, and coagulation behavior.
These biological differences can influence experimental outcomes and make it more difficult to compare results generated across laboratories or over extended research programs.
By providing standardized cryopreserved platelet preparations, Retham aims to reduce this variability while enabling researchers to generate more consistent data from experiment to experiment.
Greater reproducibility could accelerate preclinical research, improve assay validation, and facilitate multicenter collaborations where standardized laboratory materials are especially important.
Supporting Pharmaceutical and Biotechnology Development
The launch of Retham Cryoplatelets also addresses growing demand from pharmaceutical and biotechnology companies developing new therapies that interact with platelet biology.
Drug developers routinely evaluate platelet responses during preclinical testing to assess both therapeutic effectiveness and potential safety risks.
Platelet function studies play an essential role in the development of:
- Antibody-based therapeutics
- Anticoagulant medications
- Antiplatelet drugs
- Hemostasis therapies
- Cell therapies
- Gene therapies
- Novel biologic medicines
Access to reliable platelet reagents can streamline these development programs by reducing variability while improving laboratory efficiency.
Contract research organizations conducting preclinical testing on behalf of pharmaceutical sponsors may particularly benefit from products that simplify assay standardization across multiple projects.
Broad Range of Research Applications
Retham Cryoplatelets have been introduced as Research Use Only (RUO) products and are intended to support numerous laboratory applications involving platelet biology and coagulation science.
According to the company, the cryopreserved platelets can be utilized across several important research areas.
These include:
Platelet Function Assays
Researchers can evaluate platelet activation and aggregation responses using standardized platelet preparations without relying on freshly collected donor samples.
Drug Screening
The product supports preclinical evaluation of drug candidates, particularly antibody-based therapeutics that may influence platelet function or coagulation pathways.
Thrombin Generation Testing
Cryoplatelets may be incorporated into thrombin generation assays designed to assess blood coagulation potential and investigate bleeding or thrombotic disorders.
Assay Development
Diagnostic developers and laboratory scientists can utilize standardized platelet preparations when designing, validating, and optimizing new analytical methods.
These applications highlight the product’s versatility across both academic research and industrial drug development.
Scientific Innovation Behind the Technology
Company leaders described the launch as the culmination of extensive research focused on solving one of platelet science’s most persistent technical challenges.
According to Dr. Anand Padmanabhan, Chief Medical Officer of Retham Technologies, the breakthrough in platelet storage technology became possible through the company’s ongoing innovation efforts aimed at preserving platelet functionality during cryopreservation.
Developing platelets that remain biologically responsive after freezing has historically been difficult because platelet membranes and activation pathways are highly sensitive to storage conditions.
Maintaining these functional characteristics while extending shelf life represents a significant scientific achievement with potential applications across multiple areas of biomedical research.
Responding to Customer Needs
Retham executives explained that the development of Cryoplatelets was driven by direct feedback from researchers and laboratory professionals.
Curtis Jones, Vice President of Research & Innovation, noted that potential customers consistently identified fresh donor platelet dependence as a major obstacle limiting research productivity.
Many laboratories struggle with scheduling experiments around platelet availability, while others experience delays caused by inconsistent donor supplies or variable platelet quality.
The company designed Cryoplatelets to eliminate these barriers by providing a dependable resource that remains available whenever researchers require it.
This customer-centered approach shaped the product’s development and ultimately influenced its commercial launch.
Partnership with Prolytix Expands Market Access
To support broad adoption within the scientific community, Retham has partnered with Prolytix as its distribution partner.
Prolytix has established a strong reputation in coagulation, hematology, and hemostasis research, making it well positioned to introduce the product to laboratories worldwide.
The company’s existing customer relationships and scientific expertise are expected to facilitate widespread implementation of Cryoplatelets across academic institutions, pharmaceutical companies, biotechnology organizations, and CROs.
According to Dr. Steven Visuri, Chief Executive Officer of Retham Technologies, Prolytix’s extensive experience within the hemostasis research community made the company an ideal commercial partner for the new product.
Shared Commitment to Research Innovation
Prolytix also views the collaboration as an opportunity to strengthen laboratory research capabilities.
Chief Operating Officer Ryan Dorfman stated that Cryoplatelets represent an important advancement for researchers seeking improved reproducibility and greater efficiency in platelet-based studies.
He noted that the product aligns closely with Prolytix’s mission to provide laboratories with innovative technologies capable of addressing significant scientific and operational challenges.
The partnership reflects growing demand within biomedical research for standardized biological materials that simplify laboratory workflows while supporting high-quality scientific data.
Potential Impact on Future Research
As biomedical research becomes increasingly complex and data-driven, standardized laboratory reagents play a critical role in ensuring reliable experimental outcomes.
Cryopreserved functional platelets capable of maintaining biological activity over extended storage periods could substantially improve research efficiency by reducing delays, minimizing experimental variability, and enabling more flexible study designs.
Such innovations may prove particularly valuable as pharmaceutical companies continue developing increasingly sophisticated biologic therapies that require extensive platelet safety testing.
Likewise, academic investigators studying thrombosis, bleeding disorders, inflammation, cardiovascular disease, immunology, and cancer biology could benefit from immediate access to standardized platelet preparations.
The launch of Retham Cryoplatelets marks a significant milestone in platelet research technology by providing scientists with a practical alternative to traditional fresh donor platelets.
Through advanced cryopreservation techniques, the company has developed a functional platelet product designed to improve reproducibility, enhance laboratory efficiency, and support a broad range of biomedical research applications.
Supported by its new distribution partnership with Prolytix, Retham Technologies is positioning Cryoplatelets as an important research tool for laboratories seeking dependable platelet reagents that eliminate many of the logistical challenges associated with conventional platelet sourcing.
As demand continues to grow for standardized biological materials in drug discovery, assay development, coagulation research, and translational medicine, Retham Cryoplatelets have the potential to become an increasingly valuable resource for researchers working to advance scientific understanding and accelerate the development of new therapies.
About Retham Technologies, Inc.
Retham Technologies is a diagnostics company with expertise in immunoassay and platelet technologies. A key product being developed is HITDx™, an in-hospital test for heparin-induced thrombocytopenia (HIT). With HITDx, Retham seeks to improve patient outcomes while reducing unnecessary treatments and driving down healthcare costs. www.rethamtechnologies.com
About Prolytix
Prolytix, formerly Haematologic Technologies, Inc., is a leading provider of analytical and bioanalytical services supporting the research, development, and commercialization of large-molecule biotherapeutics and high-quality reagents for coagulation research. With more than 35 years of experience, Prolytix partners with clients to support drug development, assay validation, and complex analytical challenges. www.goprolytix.com